ATE290390T1 - Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand - Google Patents
Behandlung des harnblasenkrebses durch mycobacterium phlei zellwandInfo
- Publication number
- ATE290390T1 ATE290390T1 AT98962163T AT98962163T ATE290390T1 AT E290390 T1 ATE290390 T1 AT E290390T1 AT 98962163 T AT98962163 T AT 98962163T AT 98962163 T AT98962163 T AT 98962163T AT E290390 T1 ATE290390 T1 AT E290390T1
- Authority
- AT
- Austria
- Prior art keywords
- cell wall
- urinary bladder
- treatment
- bladder cancer
- phlei
- Prior art date
Links
- 241000187481 Mycobacterium phlei Species 0.000 title abstract 4
- 210000002421 cell wall Anatomy 0.000 title abstract 3
- 229940055036 mycobacterium phlei Drugs 0.000 title abstract 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title 1
- 201000005112 urinary bladder cancer Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000003932 urinary bladder Anatomy 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7511198P | 1998-02-18 | 1998-02-18 | |
| PCT/CA1998/001190 WO1999042113A1 (en) | 1998-02-18 | 1998-12-22 | Composition and method for the treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290390T1 true ATE290390T1 (de) | 2005-03-15 |
Family
ID=22123625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98962163T ATE290390T1 (de) | 1998-02-18 | 1998-12-22 | Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1054680B1 (de) |
| JP (1) | JP4426097B2 (de) |
| CN (1) | CN1153576C (de) |
| AT (1) | ATE290390T1 (de) |
| AU (1) | AU751667B2 (de) |
| CA (1) | CA2321296A1 (de) |
| DE (1) | DE69829316T2 (de) |
| DK (1) | DK1054680T3 (de) |
| ES (1) | ES2238780T3 (de) |
| NZ (1) | NZ506406A (de) |
| PT (1) | PT1054680E (de) |
| RO (1) | RO122992B1 (de) |
| WO (1) | WO1999042113A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541264A (ja) | 1999-04-08 | 2002-12-03 | ユーエイビー・リサーチ・ファウンデーション | 冨ｇオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法 |
| AU7501700A (en) * | 1999-09-29 | 2001-04-30 | Bioniche Life Sciences Inc. | Method to disrupt mitochondrial function |
| CA2395493C (en) | 1999-12-28 | 2010-06-22 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| US20030044352A1 (en) * | 2001-04-24 | 2003-03-06 | Phillips Nigel C. | Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls |
| CN101829154B (zh) * | 2010-04-23 | 2012-12-26 | 广西医科大学第一附属医院 | 防治哮喘的药物组合物的制备方法 |
| CN105943559A (zh) | 2010-10-13 | 2016-09-21 | 特莱斯塔治疗知识产权公司 | 细菌核糖核酸细胞壁组合物及其制备和使用方法 |
| TR201101874A2 (tr) | 2011-02-25 | 2011-08-22 | Leyla A�An Nac�Ye | Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100533576B1 (ko) * | 1997-08-05 | 2005-12-05 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 세포증식 및 세포사멸 조절용 조성물 및 방법 |
-
1998
- 1998-12-22 CN CNB988136597A patent/CN1153576C/zh not_active Expired - Fee Related
- 1998-12-22 NZ NZ506406A patent/NZ506406A/xx not_active IP Right Cessation
- 1998-12-22 JP JP2000532127A patent/JP4426097B2/ja not_active Expired - Fee Related
- 1998-12-22 DK DK98962163T patent/DK1054680T3/da active
- 1998-12-22 ES ES98962163T patent/ES2238780T3/es not_active Expired - Lifetime
- 1998-12-22 CA CA002321296A patent/CA2321296A1/en not_active Abandoned
- 1998-12-22 EP EP98962163A patent/EP1054680B1/de not_active Expired - Lifetime
- 1998-12-22 AT AT98962163T patent/ATE290390T1/de active
- 1998-12-22 AU AU17465/99A patent/AU751667B2/en not_active Ceased
- 1998-12-22 RO ROA200000832A patent/RO122992B1/ro unknown
- 1998-12-22 WO PCT/CA1998/001190 patent/WO1999042113A1/en not_active Ceased
- 1998-12-22 PT PT98962163T patent/PT1054680E/pt unknown
- 1998-12-22 DE DE69829316T patent/DE69829316T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NZ506406A (en) | 2002-11-26 |
| HK1030887A1 (en) | 2001-05-25 |
| CN1290171A (zh) | 2001-04-04 |
| ES2238780T3 (es) | 2005-09-01 |
| CA2321296A1 (en) | 1999-08-26 |
| JP2002503697A (ja) | 2002-02-05 |
| PT1054680E (pt) | 2005-06-30 |
| EP1054680B1 (de) | 2005-03-09 |
| DK1054680T3 (da) | 2005-06-27 |
| DE69829316T2 (de) | 2006-04-13 |
| RO122992B1 (ro) | 2010-06-30 |
| AU1746599A (en) | 1999-09-06 |
| JP4426097B2 (ja) | 2010-03-03 |
| DE69829316D1 (de) | 2005-04-14 |
| WO1999042113A1 (en) | 1999-08-26 |
| CN1153576C (zh) | 2004-06-16 |
| AU751667B2 (en) | 2002-08-22 |
| EP1054680A1 (de) | 2000-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0762898T3 (da) | Cyclodextrinsystem til levering af oligonukleotider til celler | |
| ATE223215T1 (de) | Inhibitoren der fettsäuresynthese als antimikrobielle mittel | |
| WO2002013833A3 (en) | SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 | |
| ATE516288T1 (de) | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren | |
| MY135732A (en) | 5,6-trimethylenepyrimidin - 4 - one compounds | |
| NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
| EA200001044A3 (ru) | Соединения для лечения женской сексуальной дисфункции | |
| WO2002026727A3 (en) | Methods of providing and using compounds (retinoids) having activity as inhibitors of cytochrome p450rai | |
| DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
| ATE315558T1 (de) | Verbindungen mit cytochrom p450ra1 hemmenden aktivität | |
| ATE290390T1 (de) | Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand | |
| DE69912432D1 (de) | Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide | |
| SI1147088T1 (sl) | 6-arilfenantridini s PDE-IV inhibirajoco aktivnostjo | |
| SI1147087T1 (en) | Phenanthridine-n-oxides with pde-iv inhibiting activity | |
| ATE307797T1 (de) | Aktivierte iod-verbindungen zur behandlung von krebs und aids | |
| WO2004009112A8 (en) | Use of urease for inhibiting cancer cell growth | |
| PL331104A1 (en) | Therapeutic application of bam (cd40l) technology in treating diseases related to smooth muscles | |
| WO2005032595A3 (en) | Methods and compositions for the inhibition of stat5 in prostate cancer cells | |
| EP1165106B8 (de) | Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc | |
| DE69902999D1 (de) | Glucocorticoide zur behandlung von glomerulonephitis | |
| DE69919386D1 (de) | Zusammensetzung zur behandlung von entzündungen | |
| RU2008127844A (ru) | Способы идентификации и таргетинга раковых стволовых клеток на основе морфологии ядра | |
| Kasemset et al. | Regulation of Mn-SOD activity in the mouse heart: Glucose effect | |
| Hashimoto et al. | DNA Strand Scissions by Hydroxamic Acids-Copper (II) Ion under Aerobic Conditions. | |
| ATE232734T1 (de) | Verwendung von pvp oder povidone zum reduzieren von darmschwellungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1054680 Country of ref document: EP |